Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Eficacia terapéutica y seguridad del tratamiento con RF no invasivo en la MGD refractaria

5 de noviembre de 2026 actualizado por: The University of Hong Kong

Eficacia terapéutica y seguridad del tratamiento con radiofrecuencia no invasiva en pacientes con disfunción de la glándula de Meibomio refractaria: un ensayo controlado aleatorio

The goal of this prospective, 24-week, double-masked, randomized, sham-controlled clinical trials to compare clinical efficacy and safety of RF and MGX with MGX alone in patients with meibomian gland dysfunction-related dry eye disease. The main question it aims to answer is whether radiofrequency treatment and meibomian gland expression is more effective in improving tear breakup time, as measured using non-invasive video keratography, compared with meibomian gland expression alone, in patients with refractory meibomian gland dysfunction-related dry eye disease.

Participants will be divided into two groups, one group will receive RF treatment followed with MGX and another will receive sham treatment with MGX.

Descripción general del estudio

Estado

Reclutamiento

Condiciones

Intervención / Tratamiento

Descripción detallada

Dry eye disease(DED) is a prevalent age-related ophthalmic condition. Depending on the population studied and the diagnostic criteria used, dry eye disease is estimated to have a high prevalence in most populations , with a female preponderance. In the latest 2017 Tear Film and Ocular Surface Society Dry Eye Workshop II (TFOS DEWS II) Epidemiology Report, which compiled dry eye prevalence data from studies worldwide, the reported the prevalence of DED ranged from 5 to 50%. The risk of dry eye disease increases with age, where with every increase in 10 years of age, the self-reported symptoms of DED increased by 2%. In one study in Asia, up to 70% of elderly patients greater than 60 years of age suffering from symptomatic dry eye disease. Dry eye disease causes gritty and painful eyes, with associated blurred vision. For sufferers, it poses a significant burden on quality of life and limitations activities on activities of daily living, resulting in considerable economic costs to society. A 2006 health-economics study in the United Kingdom estimated that the annual healthcare costs to the public sector for every 1000 dry eye patients was USD 1.1 million.

The causes of dry eye can be broadly classified into those with aqueous tear deficiency, excessive tear evaporation or a combination of both. The most common cause of excessive tear evaporation is meibomian gland dysfunction (MGD). This is a common condition of the eyelids where there is a significant change in both the consistency and quantity of meibum, resulting in chronic inflammation of the eyelids and subsequent ocular surface dysfunction. MGD has a prevalence from 46.2% to 69.3% in several studies targeting Asian populations, with a trend of higher prevalence in the elderly. Insufficient lipid secretion from meibomian gland undermines tear film stability, producing dry eye symptoms despite normal tear secretion. In a recent study, up to 70.3% of dry eye patients were found to have concurrent MGD. Refractory MGD is defined by the failure to respond to more than at least three types of conventional therapy, including lubricating eyedrops, gels and ointments and topical or systemic anti-inflammatory treatment, in the past two years.

Currently heat-based therapies are the mainstay and most effective strategies against MGD. Eyelid warming, thermal pulsation and intense light therapy are three prevailing heat-based treatments for MGD- related dry eye disease. Eyelid warming usually involves the application of warm towels, commercialized eye masks (EyeGiene® or Blephasteam®) or eye bags (MGDRx Eye Bag) at least twice a day. Thermal pulsation (Lipiflow®) refers to the delivery of controlled heat together with gentle massage to the eyelids by the machine for 10-17 minutes. Intense pulsed light (IPL) therapy, which uses light energy on the skin surface, is widely used in dermatology to treat a variety of conditions including dermal vascular lesions, such as port wine stains and hemangiomas, facial rosacea, and acne. Each treatment strategy however carries significant limitations. Self-applied eyelid warm compress is cheap and easily available, but when used alone has limited efficacy. Furthermore, sustained patient adherence to treatment is difficult long term. A single treatment of thermal pulsation therapy has been shown to have sustained therapeutic effects up to 12 months after treatment. However, thermal pulsation is not effective in moderate to severe cases of MGD. From existing studies, IPL has greater clinical efficacy than thermal pulsation, but its therapeutic effects are maintained for a significantly shorter period. As such, monthly repeated treatments for up to 8 months may be required for sustained effects. It is also important to note that none of the existing treatments allow the eyelids to evacuate inspissated meibum effectively, with meibum expression by an ophthalmologist an important step in the treatment process. Thus, MGD is likely to recur long-term.

The Thermage FLX System (WA, USA) is a non-ablative radiofrequency (RF) energy-based device, which has been widely adopted in the cosmetic industry for radiofrequency tissue tightening. RF transfers high energy fluences through the skin to deep dermal layers uniformly while protecting the epidermis. It is postulated that RF stimulates subdermal collagen production for tissue tightening effect. There are several advantages of using non-invasive RF treatment over other currently available energy-based devices. Firstly, the Thermage FLX has a much more precise applicator directly targeting the meibomian glands. Thermage FLX addresses both the upper and lower eyelids as close as possible to the lid margin, which is directly where the meibomian glands are situated, it also addresses the tragus area as well, hence a more precise and direct treatment area can be achieved. Secondly, compared to other energy-based devices, Thermage FLX provides a higher accumulative heat transfer effect around the periocular region, due to its repeated application of at least 4-5 cycles around the periorbital region. With higher accumulative heat energy, we anticipate a better and more effective melting of the meibum, which aids in more effective meibum expression. Thirdly, as Thermage FLX has been widely adopted for radiofrequency tissue tightening due to its collagen resynthesis effect, there has been proven improvement of the elasticity of orbicularis and periocular skin tissue, this can promote better blinking effort and better apposition of lid margins. This may enhance the pumping effect of the orbicularis oculi in the long-term. RF treatment is potentially a safe and effective multimodal treatment for MGD-related dry eye disease.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

112

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Kendrick Co SHIH
  • Número de teléfono: 94326271
  • Correo electrónico: kcshih@hku.hk

Ubicaciones de estudio

      • Hong Kong, Hong Kong
        • Reclutamiento
        • HKU Eye Centre
        • Contacto:
          • Kendrick Co SHIH
          • Número de teléfono: 94326271
          • Correo electrónico: kcshih@hku.hk
    • Hong Kong
      • Hong Kong, Hong Kong, Hong Kong
        • Reclutamiento
        • Grantham Hospital
        • Contacto:
          • Kendrick Co Shih

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  1. Age 18 or more
  2. Bilateral dry eye disease as confirmed by presence of both symptoms and signs 2.1 Symptoms: Abnormal result on the Standard Patient Evaluation of Eye Dryness Questionnaire (SPEED) dry eye symptom questionnaire (≥5) 2.2 Signs: Abnormal result in at least one of the following three clinical tests - tear osmolarity, NIKBUT and corneal staining for punctate epithelial erosions and,
  3. Bilateral moderate to severe meibomian gland dysfunction - at least Grade 1 meibum quality (cloudy appearance) and Grade 2 meibum expressibility (moderate pressure required). And,
  4. Refractory MGD - The failure to respond to at least three types of conventional therapy, including artificial tears, topical or systemic antibiotics and anti-inflammatory treatments and the aforementioned heat-based therapies, over a period of at least 2 years
  5. Fitzpatrick skin type I-IV - Type V and VI skinned subjects are excluded from the study due to the high risk of pain and focal hypopigmentation
  6. Mentally fit to give informed consent

Exclusion Criteria:

  1. Fitzpatrick skin type V-VI
  2. History of eyelid scarring
  3. Infrared meibography evidence of significant acinar gland atrophy (dropout of >30%) - these patients have been shown not to benefit from heat-based therapies due to end-stage disease
  4. Pregnancy or lactation
  5. Active corneal disease such as infectious keratitis, allergic keratoconjunctivitis, pterygium, exposure keratopathy, lagophthalmos, trichiasis or dellen
  6. Current systemic intake of photosensitive medications, including tetracycline group of drugs.
  7. History of corneal abnormality or surgery within 3 months

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Doble

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Radiofrequency treatment (RF), followed by meibomian gland expression (MGX)

Before treatment, a thermage return pad will be applied to subject's skin to help prevent electrical burns. The return pad is a rubber, non-active electrode that creates a return path for radiofrequency energy back to the thermage comfort pulse technology (CPT) system. The upper and lower lid of both eyes are marked with skin marking paper (Thermage ® Skin Marking Paper TK-3.00). Coupling fluid is then applied to the external surface of the upper and lower lids of both eyes. All subjects then receive 225 applications to each eye over the upper and lower eyelids. Immediately after treatment, meibomian gland expression will be performed on both upper and lower eyelids of each eye for both eyes of all subjects using meibum expression forceps. Pain is minimized during this procedure by topical application of 0.4% oxybuprocaine hydrochloride.

The Thermage FLX System is tested for its therapeutic efficacy and safety on treating refractory Meibomian Gland Dysfunction

Comparador falso: Sham treatment, followed by meibomian gland expression (MGX)

The training mode is used in the Thermage FLX, which simulates treatment without dissipation of radiofrequency energy. Immediately after treatment, meibomian gland expression will be performed on both upper and lower eyelids of each eye for both eyes of all subjects using meibum expression forceps. Pain is minimized during this procedure by topical application of 0.4% oxybuprocaine hydrochloride.

Sham treatment acts as a control to test the therapeutic efficacy and safety of The Thermage FLX System

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change in non-invasive keratographic tear breakup time (NIKBUT)
Periodo de tiempo: From baseline to 6 months post- treatment between study groups

NIKBUT is measured in seconds and average of 3 consecutive readings is taken. Higher values mean better outcomes.

From baseline to 6 months post- treatment between study groups

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change in Standard Patient Evaluation of Eye Dryness (SPEED) symptom score
Periodo de tiempo: From baseline to 6 months post-treatment between study groups

One number was collected per patient, with higher scores meaning worse outcomes

From baseline to 6 months post-treatment between study groups
Percentage of subjects with normal non-invasive keratographic tear breakup time (NIKBUT)
Periodo de tiempo: 6 months

> 10 seconds, with lower scores meaning worse

6 months
Percentage of subjects with normal SPEED
Periodo de tiempo: 6 months

<5, with higher scores meaning worse

6 months
Change in best corrected visual acuity
Periodo de tiempo: from baseline to 6 months post-treatment

from logmar(1.0 to -0.1)

from baseline to 6 months post-treatment
Incidence of periorbital pain
Periodo de tiempo: 6 months

at least 3/10 and above, with higher scores meaning worse

6 months
Incidence of ocular adverse events
Periodo de tiempo: 6 months

evidence of uveitis, conjunctivitis, scleritis/episcleritis, new lens opacities, new cornea opacities

6 months
Incidence of non-ocular adverse events
Periodo de tiempo: 6 months

eyelid skin burn, eyelid redness, eyelid hyper/hypopigmentation

6 months

Otras medidas de resultado

Medida de resultado
Medida Descripción
Periodo de tiempo
Change in cornea staining (National Eye Institute Grading System)
Periodo de tiempo: from baseline to 6 months post-treatment

This serves as an objective parameter for ocular surface damage, with higher scores meaning worse

from baseline to 6 months post-treatment
Tear osmolarity
Periodo de tiempo: from baseline to 6 months post-treatment

This serves as an objective parameter for ocular surface damage

from baseline to 6 months post-treatment
Change in Shirmer's I test reading
Periodo de tiempo: from baseline to 6 months post-treatment

In millimetres. Readings serve as objective parameters for tear volume

from baseline to 6 months post-treatment
Tear meniscus height
Periodo de tiempo: from baseline to 6 months post-treatment

In millimetres. Readings serve as objective parameters for tear volume

from baseline to 6 months post-treatment
Changes in meiboscore
Periodo de tiempo: from baseline to 6 months post-treatment between study groups

These readings serve as parameters for meibomian gland dysfunction

from baseline to 6 months post-treatment between study groups
Changes in meibum expressibility
Periodo de tiempo: from baseline to 6 months post-treatment between study groups

These readings serve as parameters for meibomian gland dysfunction, with higher scores meaning worse

from baseline to 6 months post-treatment between study groups
Changes in meibum quality
Periodo de tiempo: from baseline to 6 months post-treatment between study groups

These readings serve as parameters for meibomian gland dysfunction, with higher scores meaning worse

from baseline to 6 months post-treatment between study groups

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Investigador principal: Kendrick Co SHIH, The University of Hong Kong, Grantham Hospital

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Publicaciones Generales

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

22 de octubre de 2024

Finalización primaria (Estimado)

30 de octubre de 2027

Finalización del estudio (Estimado)

31 de diciembre de 2027

Fechas de registro del estudio

Enviado por primera vez

10 de diciembre de 2023

Primero enviado que cumplió con los criterios de control de calidad

22 de enero de 2024

Publicado por primera vez (Actual)

24 de enero de 2024

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

9 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

5 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • 11221686

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

Sí

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .